CERA

Hope in sight TM

Our research is bringing hope to people affected by vision loss and blindness

Donate Now

Hope in Sight Giving Day

Be a beacon of hope for vision research by helping us raise $150,000. Donate on Hope in Sight Giving Day to triple your impact on our work to find cures for inherited retinal diseases.

Science and Research

Learn how CERA’s next generation gene therapy research could transform the treatment of eye diseases including age-related macular degeneration and diabetic eye disease.

Consumer involvement

Our new Consumer Program is working alongside people with lived experience to ensure their insights are at the heart of advancing eye research. Learn about the program and meet our Consumer Advisory Group.

Celebrating Cerulea Clinical Trials

Cerulea Clinical Trials, CERA’s new not-for-profit clinical trials centre, is up and running.
Learn how Cerulea will transform the delivery of ophthalmic clinical trials, increase community access to sight-saving therapies and deliver excellence for clinicians, trial participants and sponsors.

Read more

Take part in research

Help shape the future of vision research by taking part in a clinical study.
Find out how you can take part in studies at CERA and Cerulea Clinical Trials for eye conditions including age-related macular degeneration, corneal conditions, diabetic retinopathy, glaucoma and inherited retinal disease.

Learn more

Latest News


News

16 October 2024

CERA’s Consumer Advisory Group will bring the voices of consumers into the heart of vision research.

Research

19 September 2024

Researchers at CERA are working to expand gene therapy technology to increase the number of treatments for blindness-causing genetic disorders.

News

12 September 2024

New Australian Government policy removes barriers to genetic testing – encouraging early diagnosis and participation in clinical trials that could transform the future of personalised medicine and gene therapy for eye diseases.

News

08 August 2024

A new report has named vision loss as a risk factor that could be modified to reduce the chance of developing dementia.

Eye-news emails are sent to subscribers once a month

Newsletter Subscribe
Receive Appeals